Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Crispr Therapeutics Ag (NQ: CRSP)
29.54 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 9:27 AM EST, Dec 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 498
Open 29.54
Bid (Size) 29.25 (5)
Ask (Size) 29.70 (2)
Prev. Close 29.54
Today's Range 29.54 - 29.54
52wk Range 18.66 - 73.90
Shares Outstanding 46,842,969
Dividend Yield N/A
Performance
YTD
+17.36%
+17.36%
1 Month
-13.22%
-13.22%
3 Month
-44.45%
-44.45%
6 Month
-52.40%
-52.40%
1 Year
+48.14%
+48.14%
Top News
More News
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief... Read More
from GlobeNewswire News Releases
Gene-Editing Stocks Took Stutter Steps Forward in 2018
Top biotech stocks are making progress, but it was slow going this year. Read More
category Market News , CRSP
from Motley Fool
More News
Read More
Under Armour Tanks on Guidance
category CRSP , JNJ , CTAS , and 10 more.
from Motley Fool
2 Sets of Disasters Biotech Will Pay For in 2019
category CRSP , NVS , ONCE , and 3 more.
from Motley Fool
3 High-Growth Stocks That Are Just Getting Started
category APPN , CRSP , CVNA , and 1 more.
from Motley Fool
Top 10 Healthcare Stories of 2018
category CVS , Market News , CELG , and 7 more.
from Motley Fool
Here's Why Crispr Therapeutics Rose 17% in November
category Market News , CRSP
from Motley Fool
January 2019 Options Now Available For CRISPR Therapeutics (CRSP)
category Stocks
from Market News Video
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
category CRSP , Market News , SNY , and 2 more.
from Motley Fool
Implied JKK Analyst Target Price: $231
category ETFs
from ETF Channel
This Biotech Stock Could Launch Its First CRISPR Drug In 2022
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.